Search
DOTMP HO-166
go.drugbank.com/drugs/DB05380ExperimentalIt is an experimental therapy that is being developed by NeoRx Corporation.
Netilmicin
go.drugbank.com/drugs/DB00955ApprovedNetilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.
Mixtures: NETEX SIFIArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].
Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLECategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsPhenylacetic acid
go.drugbank.com/drugs/DB09269ApprovedPhenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.
Halofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnHalofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesAcetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10799ApprovedInvestigationalNeisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10800ApprovedInvestigationalNeisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Reviparin
go.drugbank.com/drugs/DB09259Approved[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]
Pramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].